Imcheck Therapeutics
Edit

Imcheck Therapeutics

https://www.imchecktherapeutics.com/
Last activity: 17.07.2023
Categories: ManagementResearchWebsiteActiveDevelopmentHealthTech
ImCheck Therapeutics is designing and developing a new generation of immunotherapy antibodies positioned at the crossroads of two high-potential immunological fields: γ9δ2 T cells and a novel super-family of immunomodulators, butyrophilins. Due to their mechanism of action, and notably their ability to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior anti-cancer efficacy as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, overcome the resistance to this class of agents. Activated γ9δ2 T cells also have therapeutic potential in infectious diseases (e.g., bacteria and viruses), while antagonist antibodies have potential as treatments for a range of autoimmune diseases. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
Followers
4.3K
Mentions
16
Location: France, Provence-Alpes-Côte d'Azur, Marseille
Employees: 11-50
Total raised: $175.37M
Founded date: 2015

Investors 7

Funding Rounds 3

DateSeriesAmountInvestors
14.06.2022-$100.5M-
04.12.2019Series B$53M-
02.05.2017Series A$21.87M-

Mentions in press and media 16

DateTitleDescriptionSource
17.07.2023Earlybird Health's Inaugural Impact & ESG report reveals...Whether you like it or not, you'll be hearing a lot about ESG (Environmental Social Governance) metr...tech.eu/20...
13.06.2022ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Fina...Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, ...globenewsw...
13.06.2022With stacked to-do list, ImCheck checks off next funding rou...A phase 2 trial ready to expand? Check. Plans for combination studies? Check. More pipeline assets t...fiercebiot...
13.06.2022ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Fina...ImCheck Therapeutics announced today the close of a EUR 96 million (USD 103 million) financing, co-l...anderapart...
21.10.2021ImCheck Publishes Comprehensive Overview of the Development ...ImCheck Therapeutics announced the publication of the preclinical to clinical development of its lea...wellington...
17.09.2021ImCheck Presents Preliminary Patient Response Data from the ...ImCheck Therapeutics today presented data at the ESMO Congress 2021 from its ongoing EVICTION Phase ...wellington...
09.04.2021Clinical Data with ImCheck’s ICT01 to be Presented at AACR: ...ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα l...wellington...
15.09.2020ImCheck Announces Investment by BB Pureos Bioventures to Clo...ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €5...marketscre...
15.09.2020GIMV NV Gimv : ImCheck Announces Investment by BB Pureos Bi...Marseille, France, September 15, 2020 - ImCheck Therapeutics today announced that it has secured an ...marketscre...
26.03.2020First patient dosed in EVICTION trial evaluating ImCheck’s l...ImCheck Therapeutics has dosed the first patient in a Phase I/IIa clinical trial evaluating ICT01, a...wellington...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In